Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Dexcom

Do Wall Street Analysts Like DexCom Stock?

Despite trailing the broader market over the past year, DexCom continues to attract strong optimism from Wall Street analysts, who maintain a highly positive outlook on the stock's long-term potential.

Barchart

DexCom Stock: Earnings Beat and New Market Access Drive Bull Case

Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market.

MarketBeat

Oura brings AI-powered meals and glucose tracking to the US

Oura launches two metabolic features within the Oura app that help users track their meals, rise in glucose levels to manage their eating habits.

Android Central

From analysis to the latest developments in health,
read the most diverse news in one place.

Is DexCom Stock Underperforming the Dow?

DexCom significantly underperformed the Dow over the past year, yet analysts remain strongly bullish on the stock’s long term prospects.

Barchart

DexCom Stock Outlook: Is Wall Street Bullish or Bearish?

Although DexCom has significantly lagged behind the broader market over the past year, Wall Street analysts remain strongly optimistic about the stock's prospects.

Barchart

What to Expect From DexCom's Q4 2024 Earnings Report

DexCom is gearing up to release its fourth-quarter earnings next month, and analysts forecast single-digit profit growth.

Barchart

The Oura Ring is about giving your body a voice, says Oura CEO

The Oura Ring 4 set a standard in the smart ring industry, and its CEO is excited for the future to make Oura the ring connected to our health.

Android Central

Read news from The Economist, FT, and more,
with one subscription

Is DexCom Stock Underperforming the Nasdaq?

Despite DexCom's lagging performance relative to the Nasdaq Composite over the past year, Wall Street analysts maintain a strong bullish outlook on the stock's prospects.

Barchart

Key Takeaways From DexCom Analyst Ratings

DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

The Stelo glucose biosensor changed the way I manage my diabetes - I tested it for two weeks, and here's how it went

The Stelo glucose biosensor is more affordable and accessible, but how well does it work for diabetics?

TechRadar

Dexcom Glucose Data To Be Integrated With ŌURA Rings

Dexcom and ŌURA have partnered to integrate Dexcom's glucose biosensing feature with the ŌURA Ring's health metrics to help improve consumers' metabolic health.

International Business Times

Your Oura Ring will be able to show you glucose readings in 2025 – thanks to Dexcom integration

The company is now valued at over $5 billion

TechRadar

Are Wall Street Analysts Predicting DexCom Stock Will Climb or Sink?

Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Nick Jonas wants to 'take bigger risks' as he reflects on 'wild' Jonas Brothers milestone

EXCLUSIVE The singer-songwriter and actor has crammed a lot into his 32 years of life and the ‘incredibly ambitious and driven’ star is determined there will be a lot more to come

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Barchart

Here's What to Expect From DexCom's Next Earnings Report

DexCom is poised to announce its third-quarter results later this month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

Is DexCom Stock Underperforming the S&P 500?

Despite DexCom’s underperformance compared to the S&P 500 Index over the past year, Wall Street analysts are highly bullish about the stock’s prospects.

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Wall Street Bullish or Bearish on DexCom Stock?

Despite DexCom lagging behind the broader market over the past year, Wall Street analysts remain bullish on the stock’s prospects.

Kiplinger

Stock Market Today: Dow Adds 654 Points as 3M Stock Explodes Higher

It was a risk-on day for stocks thanks to an upbeat inflation reading and impressive earnings from 3M and Deckers.

Kiplinger

Dexcom Stock Sinks on Sales Miss, Guidance Cut: What to Know

Dexcom stock is crashing Friday after the glucose monitoring company reported dismal Q2 revenue and slashed its full-year sales guidance. Here's what you need to know.

Barchart

3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

Tom’s Guide

Your Apple Watch can track blood sugar levels — here's how with Dexcom G7

Learn to set up and use the Dexcom G7 CGM system with your Apple Watch for convenient, real-time blood sugar monitoring.

Barchart

Earnings Preview: What to Expect From DexCom's Report

DexCom is gearing up to announce its second-quarter results this month, and analysts are anticipating a double-digit increase in the company’s bottom-line figure.

Barchart

How Is DexCom's Stock Performance Compared to Other Medical Devices Stocks?

Despite DexCom’s underperformance compared to its industry, Wall Street analysts remain optimistic about the stock’s prospects.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.